{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Ecopladib) is a sub-micromolar inhibitor of cytosolic phospholipase A2α (cPLA2α, type IVA phospholipase). Inhibitors of cPLA2alpha are predicted to be efficacious in treating asthma as well as the signs and symptoms of osteoarthritis, rheumatoid arthritis, and pain. It displayed oral efficacy in the rat carrageenan air pouch and rat carrageenan-induced paw edema models.
Status:
Investigational
Source:
NCT00327002: Phase 2 Interventional Completed Metabolic Syndrome X
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
LY-518674 is a highly potent and selective proliferator-activated receptor (PPAR)-alpha agonist. LY-518674 produced a much greater increase in serum high-density lipoprotein-cholesterol (HDL-c) than the known fibrate drugs. The increase in HDL-c was associated with de novo synthesis of apolipoprotein A-1. It was being developed for the treatment of dyslipidemias with atherogenic potential.
Class (Stereo):
CHEMICAL (ACHIRAL)
Meglitinide (HB 699) is an antidiabetic compound. Meglitinide is a short-acting insulin secretagogue that targets one of the main defects that characterizes type 2 diabetes: the progressive loss of early phase prandial insulin secretion. It acts in a glucose-dependent manner to close adenosine triphosphate (ATP)-dependent potassium channels on the β-cell membrane, depolarize the β-cell, resulting in the opening of calcium channels, increased calcium influx and insulin secretion.
Class (Stereo):
CHEMICAL (ACHIRAL)
Lexofenac is an ibufenac derivative. It was developed as anti-inflammatory and analgesic agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Suxemerid is a succinic acid derivative patented by Warner-Lambert Pharmaceutical Co. as an antihypertensive agent.
Status:
Investigational
Source:
NCT00052117: Phase 2 Interventional Completed HIV Infections
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Capravirine (S-1153, AG1549) is a 1,2,4,5-tetrasubstituted imidazole derivative patented by pharmaceutical company Shionogi as specific inhibitors of HIV-1 reverse transcriptase. However, safety and efficacy studies showed that Capravirine had no specific advantages over currently used NNRTIs. Consequently, clinical trials were discontinued after phase IIb.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Clofenamic acid is a derivative of anthranilic acid, discovered by Parke-Davis. It possesses anti-inflammatory activity in the carrageenan-induced rat foot edema test.
Status:
Investigational
Source:
INN:clinolamide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Clinolamide (cyclohexylamine of linoleic acid) is a drug developed by a Japanese company Sumitomo Chemical Co. Ltd. Clinolamide has been found to lower serum and liver cholesterol levels and to reduce the severity of atherosclerosis in cholesterol-fed rabbits.
Status:
Investigational
Source:
NCT01064037: Phase 2 Interventional Terminated Heart Failure
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Cinaciguat acts specifically on oxidized/haem-free soluble guanylyl cyclase by binding to the enzyme's haem pocket and mimicking the nitric-oxide-bound haem group. It is in clinical development for the treatment of acute decompensated heart failure. Cinaciguat had been in phase II clinical trials. However, trials were terminated early because of an excess of hypotension in the cinaciguat arms and subsequent slow enrolment.
Class (Stereo):
CHEMICAL (RACEMIC)
FLESTOLOL is an ultra-short-acting beta-adrenergic blocking agent without any intrinsic sympathomimetic activity.
